Vanguard Capital Management’s Candel Therapeutics CADL Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$30.8M Buy
2,947,019
+252,979
+9% +$2.8M ﹤0.01% 2164
2026
Q2
$27.7M Buy
2,694,040
+231,283
+9% +$1.75M ﹤0.01% 2277
2026
Q1
$12.1M Buy
+2,462,757
New +$13.4M ﹤0.01% 2626

Other funds holding CADL

Vanguard Capital Management's CADL Position: Q3 2026 in Review

Vanguard Capital Management increased its Candel Therapeutics (CADL) stake by 9.4% in Q3 2026, buying an estimated $2.8M and bringing the position to 2,947,019 shares worth $30.8M. The position accounts for ﹤0.01% of the portfolio, ranked #2164.

Vanguard Capital Management first reported a position in CADL in Q1 2026 and has held it in 3 quarters since. 141 funds tracked by Wall St. Rank hold CADL as of Q3 2026.

  • Vanguard Capital Management held 2,947,019 shares of Candel Therapeutics worth $30.8M as of Q3 2026.
  • Vanguard Capital Management bought 252,979 Candel Therapeutics shares in Q3 2026, an estimated $2.8M.
  • Candel Therapeutics made up ﹤0.01% of Vanguard Capital Management's portfolio in Q3 2026, its #2164 holding.
  • Vanguard Capital Management first reported a position in Candel Therapeutics in Q1 2026 and has held it in 3 quarters since.
  • 141 funds tracked by Wall St. Rank held Candel Therapeutics as of Q3 2026.

Based on Vanguard Capital Management's 13F filing for Q3 2026, filed 13 Nov 2026.